Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery

Maurie Markman, David S Alberts, Stephen Rubin, Thomas Hakes, John L. Lewis, Bonnie Reichman, Walter Jones, John Curtin, Richard Barakat, Franc Brodar, Yei Mei Peng, Kellie Pennie, Lois Almadrones, William Hoskins

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In clinical trials examining the intraperitoneal (ip) administration of mitoxantrone as therapy of platinum-refractory small-volume residual ovarian cancer, the characteristic "blue color" of the agent has been demonstrated to stain the surface of the peritoneal cavity and to persist for ≥1 month following the last course of therapy. To determine if this blue staining material contains potentially cytotoxic concentrations of mitoxantrone, we analyzed tissue obtained at exploratory laparotomy in six women who had last received the agent administered ip from 6-22 weeks prior to surgery. Concentrations of mitoxantrone ranged from <0.1 to 13.8 μg/g of tissue examined. Since any mitoxantrone present on the peritoneal surface will be highly protein bound, any residual drug may not have cytotoxic potential. The dose-response curves of mitoxantrone in a human clonogenic cytotoxicity assay against the RPMI 2780/S human ovarian cell line were virtually identical when the cells were incubated in either 5 or 50% fetal bovine serum, suggesting that protein binding will not significantly impair mitoxantrone-induced tumor cell killing. We conclude that the ip administration of mitoxantrone may lead to prolonged exposure of surface tumor to the high local concentrations of the active cytotoxic agent. This effect may contribute significantly to the antineoplastic potential of ip mitoxantrone in patients with small-volume residual ovarian cancer.

Original languageEnglish (US)
Pages (from-to)185-188
Number of pages4
JournalGynecologic Oncology
Volume48
Issue number2
DOIs
StatePublished - Feb 1993

Fingerprint

Mitoxantrone
Peritoneal Cavity
Residual Neoplasm
Ovarian Neoplasms
Cytotoxins
Platinum
Protein Binding
Antineoplastic Agents
Laparotomy
Blood Proteins
Neoplasms
Coloring Agents
Color
Clinical Trials
Staining and Labeling
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery. / Markman, Maurie; Alberts, David S; Rubin, Stephen; Hakes, Thomas; Lewis, John L.; Reichman, Bonnie; Jones, Walter; Curtin, John; Barakat, Richard; Brodar, Franc; Peng, Yei Mei; Pennie, Kellie; Almadrones, Lois; Hoskins, William.

In: Gynecologic Oncology, Vol. 48, No. 2, 02.1993, p. 185-188.

Research output: Contribution to journalArticle

Markman, M, Alberts, DS, Rubin, S, Hakes, T, Lewis, JL, Reichman, B, Jones, W, Curtin, J, Barakat, R, Brodar, F, Peng, YM, Pennie, K, Almadrones, L & Hoskins, W 1993, 'Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery', Gynecologic Oncology, vol. 48, no. 2, pp. 185-188. https://doi.org/10.1006/gyno.1993.1031
Markman, Maurie ; Alberts, David S ; Rubin, Stephen ; Hakes, Thomas ; Lewis, John L. ; Reichman, Bonnie ; Jones, Walter ; Curtin, John ; Barakat, Richard ; Brodar, Franc ; Peng, Yei Mei ; Pennie, Kellie ; Almadrones, Lois ; Hoskins, William. / Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery. In: Gynecologic Oncology. 1993 ; Vol. 48, No. 2. pp. 185-188.
@article{35ffa9d4ad724bd2aabba34c73636233,
title = "Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery",
abstract = "In clinical trials examining the intraperitoneal (ip) administration of mitoxantrone as therapy of platinum-refractory small-volume residual ovarian cancer, the characteristic {"}blue color{"} of the agent has been demonstrated to stain the surface of the peritoneal cavity and to persist for ≥1 month following the last course of therapy. To determine if this blue staining material contains potentially cytotoxic concentrations of mitoxantrone, we analyzed tissue obtained at exploratory laparotomy in six women who had last received the agent administered ip from 6-22 weeks prior to surgery. Concentrations of mitoxantrone ranged from <0.1 to 13.8 μg/g of tissue examined. Since any mitoxantrone present on the peritoneal surface will be highly protein bound, any residual drug may not have cytotoxic potential. The dose-response curves of mitoxantrone in a human clonogenic cytotoxicity assay against the RPMI 2780/S human ovarian cell line were virtually identical when the cells were incubated in either 5 or 50{\%} fetal bovine serum, suggesting that protein binding will not significantly impair mitoxantrone-induced tumor cell killing. We conclude that the ip administration of mitoxantrone may lead to prolonged exposure of surface tumor to the high local concentrations of the active cytotoxic agent. This effect may contribute significantly to the antineoplastic potential of ip mitoxantrone in patients with small-volume residual ovarian cancer.",
author = "Maurie Markman and Alberts, {David S} and Stephen Rubin and Thomas Hakes and Lewis, {John L.} and Bonnie Reichman and Walter Jones and John Curtin and Richard Barakat and Franc Brodar and Peng, {Yei Mei} and Kellie Pennie and Lois Almadrones and William Hoskins",
year = "1993",
month = "2",
doi = "10.1006/gyno.1993.1031",
language = "English (US)",
volume = "48",
pages = "185--188",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery

AU - Markman, Maurie

AU - Alberts, David S

AU - Rubin, Stephen

AU - Hakes, Thomas

AU - Lewis, John L.

AU - Reichman, Bonnie

AU - Jones, Walter

AU - Curtin, John

AU - Barakat, Richard

AU - Brodar, Franc

AU - Peng, Yei Mei

AU - Pennie, Kellie

AU - Almadrones, Lois

AU - Hoskins, William

PY - 1993/2

Y1 - 1993/2

N2 - In clinical trials examining the intraperitoneal (ip) administration of mitoxantrone as therapy of platinum-refractory small-volume residual ovarian cancer, the characteristic "blue color" of the agent has been demonstrated to stain the surface of the peritoneal cavity and to persist for ≥1 month following the last course of therapy. To determine if this blue staining material contains potentially cytotoxic concentrations of mitoxantrone, we analyzed tissue obtained at exploratory laparotomy in six women who had last received the agent administered ip from 6-22 weeks prior to surgery. Concentrations of mitoxantrone ranged from <0.1 to 13.8 μg/g of tissue examined. Since any mitoxantrone present on the peritoneal surface will be highly protein bound, any residual drug may not have cytotoxic potential. The dose-response curves of mitoxantrone in a human clonogenic cytotoxicity assay against the RPMI 2780/S human ovarian cell line were virtually identical when the cells were incubated in either 5 or 50% fetal bovine serum, suggesting that protein binding will not significantly impair mitoxantrone-induced tumor cell killing. We conclude that the ip administration of mitoxantrone may lead to prolonged exposure of surface tumor to the high local concentrations of the active cytotoxic agent. This effect may contribute significantly to the antineoplastic potential of ip mitoxantrone in patients with small-volume residual ovarian cancer.

AB - In clinical trials examining the intraperitoneal (ip) administration of mitoxantrone as therapy of platinum-refractory small-volume residual ovarian cancer, the characteristic "blue color" of the agent has been demonstrated to stain the surface of the peritoneal cavity and to persist for ≥1 month following the last course of therapy. To determine if this blue staining material contains potentially cytotoxic concentrations of mitoxantrone, we analyzed tissue obtained at exploratory laparotomy in six women who had last received the agent administered ip from 6-22 weeks prior to surgery. Concentrations of mitoxantrone ranged from <0.1 to 13.8 μg/g of tissue examined. Since any mitoxantrone present on the peritoneal surface will be highly protein bound, any residual drug may not have cytotoxic potential. The dose-response curves of mitoxantrone in a human clonogenic cytotoxicity assay against the RPMI 2780/S human ovarian cell line were virtually identical when the cells were incubated in either 5 or 50% fetal bovine serum, suggesting that protein binding will not significantly impair mitoxantrone-induced tumor cell killing. We conclude that the ip administration of mitoxantrone may lead to prolonged exposure of surface tumor to the high local concentrations of the active cytotoxic agent. This effect may contribute significantly to the antineoplastic potential of ip mitoxantrone in patients with small-volume residual ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027452850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027452850&partnerID=8YFLogxK

U2 - 10.1006/gyno.1993.1031

DO - 10.1006/gyno.1993.1031

M3 - Article

C2 - 8428689

AN - SCOPUS:0027452850

VL - 48

SP - 185

EP - 188

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -